Therapeutic Purpose and Mechanism of Action

Isoket is a medication belonging to the group of organic nitrates. Its primary function is to facilitate the relaxation of smooth muscles in the walls of blood vessels. This effect, known as vasodilation, occurs in both peripheral arteries and veins, though the impact on the venous system is more pronounced.

By dilating the veins, the medication reduces the volume of blood returning to the heart, which lowers the pressure within the cardiac chambers. Simultaneously, the dilation of arterial vessels reduces the resistance the heart must overcome to pump blood throughout the body. These combined actions decrease the heart's overall workload and its demand for oxygen.

Main Uses

Isoket is primarily used for the management and prevention of conditions related to coronary artery disease. Its applications include:

• Angina Pectoris: The medication is used to prevent and quickly terminate acute episodes of chest pain (angina) caused by a temporary lack of oxygen to the heart muscle. It is effective for stable angina (exertional) and vasospastic angina.
• Acute Myocardial Infarction: In clinical settings, it may be utilized during the acute phase of a heart attack to reduce the area of damage and manage complications.
• Heart Failure: It is used as part of a therapeutic regimen for chronic heart failure or acute left ventricular failure to alleviate the pressure on the heart and improve circulatory efficiency.

Clinical Benefits

The regular or acute use of Isoket provides several physiological benefits aimed at stabilizing cardiac function:

• Oxygen Balance: By lowering the heart's oxygen requirements and improving blood flow through the collateral vessels, it helps restore the balance between oxygen supply and demand.
• Pain Relief: The rapid dilation of coronary arteries helps resolve the ischemia (restricted blood supply) that causes intense chest pain.
• Improved Exercise Tolerance: In patients with chronic coronary artery disease, the reduction in cardiac workload can lead to an improved ability to perform physical activities without triggering symptoms.
• Hemodynamic Stabilization: In cases of heart failure, the medication helps reduce pulmonary congestion by lowering the filling pressure of the heart.

Regulatory References

1. NIH MedlinePlus overview

This section outlines the official eligibility and non-eligibility requirements for Изокет (Isosorbide Dinitrate) based strictly on governmental regulatory documents.

Populations Strictly Contraindicated (Must Not Use)

Official labels define absolute contraindications for patients with:

• Concomitant Therapy: Use of phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil, vardenafil) or the soluble guanylate cyclase (sGC) stimulator riociguat is strictly prohibited due to the risk of severe, life-threatening hypotension.
• Hypersensitivity: Known allergy or idiosyncrasy to isosorbide dinitrate or other organic nitrates.
• Acute Circulatory Conditions: Acute circulatory failure (shock, vascular collapse), severe hypotension (e.g., systolic blood pressure typically below 90 mmHg), marked anemia, and specific conditions like hypertrophic obstructive cardiomyopathy, constrictive pericarditis, or cardiac tamponade.
• Increased Pressure: Conditions associated with increased intracranial pressure, such as cerebral hemorrhage or head trauma.

Populations Under Restricted or Cautionary Use

Special medical consideration and caution are required for patients with:

• Organ Impairment: Severe liver disease or severe renal disease.
• Circulatory Status: Existing hypoxaemia (low oxygen in blood) due to lung disease or ischemic heart failure, or conditions causing low filling pressure.
• Pregnancy and Lactation: Safety has not been established. Use during pregnancy or while breastfeeding is not recommended unless considered essential and is solely under continuous medical supervision.
• Pediatrics: The safety and efficacy have not been established in children, rendering this population generally ineligible.

Interactions with other medicines and products

Isosorbide Dinitrate (Изокет) has officially documented interaction patterns that are classified mainly as pharmacodynamic potentiations, increasing the risk of severe blood pressure reduction.

Classification	Officially Documented Interacting Entities
Absolute Contraindications	Phosphodiesterase-5 (PDE5) Inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil, Avanafil) and Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat).
Additive Potentiation Risk	Other Vasodilators and Antihypertensive Agents (including Beta-Blockers, Calcium Channel Blockers, and Diuretics); Alcohol (Ethanol); Agents that increase the risk of Methemoglobinemia (e.g., Aminosalicylic acid, Benzocaine, Chloroquine).

Co-administration with all PDE5 Inhibitors and sGC Stimulators is formally contraindicated by regulatory authorities due to the confirmed risk of severe hypotension and cardiovascular collapse. This restriction is based on the potentiation of the vasodilatory effect. Official guidance specifies that if a nitrate must be administered after a PDE5 inhibitor, a mandatory time separation is required, typically 24 hours after Sildenafil or Vardenafil and 48 hours after Tadalafil.

The regulatory documents describe that concomitant use with alcohol may enhance the hypotensive effect, which can lead to lightheadedness or syncope. For oral sustained-release tablets, taking the medicine with a high-fat meal may increase the absorption and systemic exposure of the drug. The risk of symptomatic hypotension is also officially noted to be heightened in patient populations who are volume-depleted or already hypotensive.

The Molecular Mechanism: Nitric Oxide (NO) Generation

The action of Isosorbide Dinitrate ( ISDN) is defined by a precise molecular cascade that leads to systemic vascular relaxation and lowered mechanical work on the heart. The drug acts as an inactive prodrug, which is converted by enzymes (e.g., ALDH2) inside vascular cells to release the signaling molecule, Nitric Oxide ( NO). NO acts as the key chemical effector, activating the enzyme Soluble Guanylate Cyclase (sGC), which initiates the cGMP-dependent relaxation pathway.

---

Cellular Effect: Smooth Muscle Relaxation

Following sGC activation, high levels of the second messenger cGMP are produced, leading to the activation of Protein Kinase G ( PKG). This process results in the dephosphorylation of Myosin Light Chain (MLC) and a reduction in intracellular Ca^2+ levels, culminating in the complete relaxation and widening (vasodilation) of the blood vessel walls, particularly in the venous circulation.

---

Systemic Outcome: Modulation of Cardiac Preload

The resulting widespread venous dilation significantly increases the capacity of the circulatory system. This physiological change reduces the volume and pressure of blood returning to the heart (known as cardiac preload). This reduction in filling pressure lowers the mechanical work performed by the heart muscle per beat.

Official Administration Guidelines for Isosorbide Dinitrate Solution

The following instructions for the use of Isosorbide Dinitrate (often branded as Isoket) are intended for professional use in a clinical setting.

Administration Scope	Official Guideline
Route of Administration	Intravenous (IV) Infusion (following mandatory dilution) or Intracoronary (IC) Injection.
Standard Adult Dosing	IV Infusion: Dosing is typically titrated (adjusted) according to patient response, usually starting between 2 mg/hour and 12 mg/hour. Doses up to 20 mg/hour may be necessary. IC Injection: The usual dose is a 1 mg bolus prior to balloon inflation, not to exceed 5 mg over 30 minutes.
Preparation Requirement	The concentrated solution must be diluted with a suitable infusion fluid (e.g., 0.9% Sodium Chloride or 5% Glucose) prior to IV infusion. The diluted solution must never be injected as an undiluted bolus intravenously.
Age-Group Rules	Elderly: Dose should be adjusted based on the patient's clinical response. Paediatric: Safety and efficacy have not been established in children.
Special Conditions	Administration must avoid PVC or PU tubing and giving sets due to significant drug adsorption onto these plastics. The patient's blood pressure and pulse must be closely monitored during administration.

Official Procedural Structure:

1. Dilution: Dilute the Isosorbide Dinitrate concentrate solution with an approved infusion fluid under aseptic conditions.
2. Delivery System: Administer the prepared admixture using a glass or rigid plastic syringe pump or infusion system.
3. Initiation and Monitoring: Initiate the IV infusion at the specified starting rate, continuously monitoring the patient's vital signs.
4. Titration: Adjust the infusion rate within the approved range based on the patient’s clinical response.

The Role of Isosorbide Dinitrate in Cardiovascular Therapy

Isosorbide dinitrate, the active substance in Изокет, belongs to the nitrate class of medications. Clinical research focuses primarily on its use in the management of angina pectoris (chest pain) and certain forms of heart failure.

---

Evidence in Angina Pectoris

Controlled clinical trials have examined the anti-anginal activity of isosorbide dinitrate. Single oral doses have been associated with a reduction in exercise-related angina that may persist for several hours in some individuals. However, studies involving multiple-dose oral regimens over several weeks have indicated that the statistically significant anti-anginal effect is often limited to a shorter duration (e.g., approximately two hours) after dosing, which is understood to be related to the potential for nitrate tolerance development.

To help maintain the intended effectiveness in chronic treatment, a daily nitrate-free interval is typically incorporated into the dosing schedule, based on clinical experience with organic nitrates.

---

Evidence in Heart Failure

Isosorbide dinitrate, often in combination with a hydralazine-class drug, has been studied in patients with heart failure with reduced ejection fraction (HFrEF). Research, including findings from major clinical trials, observed that this combination may be associated with improved exercise capacity and quality of life in this patient population. Subgroup analyses from past trials have suggested a particular benefit in African-American patients with HFrEF.

Its intravenous formulation has been assessed for use in acute settings, such as acute myocardial infarction when complicated by elevated pulmonary artery wedge pressure, and for severe or unstable angina pectoris, where its application is based on its rapid hemodynamic effects.

---

Note on Hemodynamics: The action of this medication involves the relaxation of vascular smooth muscle, which decreases venous return to the heart and systemic vascular resistance (both preload and afterload). This physiological effect is thought to contribute to the clinical observations in both angina and heart failure studies.

Common questions about Изокет (FAQ)

Q: Does Изокет affect blood pressure?

A: Yes, according to official product information, Изокет (Isosorbide Dinitrate) can cause a drop in blood pressure, a condition known as hypotension. This effect relates to the medicine's function of relaxing blood vessels. Regulatory documents confirm that monitoring of blood pressure is an important consideration during treatment with this medicine.

Q: Can I take Изокет if I have glaucoma?

A: Regulatory documents state that Изокет should be used with caution in patients with glaucoma (increased pressure in the eye). This is because the medication may, in certain circumstances, affect intraocular pressure. Regulatory guidance suggests a healthcare professional should assess the risks and benefits in this clinical situation.

Q: What should I do if I forget to take a dose of Изокет?

A: According to the official product information, if a dose is missed, regulatory documents typically advise that it may be taken when remembered. However, if it is close to the time of the next scheduled dose, official guidance usually suggests skipping the missed dose and returning to the regular schedule. Taking a double dose to make up for the missed one is generally advised against.

Q: Can I drink alcohol while taking Изокет?

A: Official product information advises that the simultaneous use of Изокет and alcohol can intensify the blood pressure-lowering effect of the medicine. This interaction may lead to severe hypotension (very low blood pressure) and symptoms such as dizziness or fainting. Therefore, official product information recommends avoiding or limiting the consumption of alcohol while using this medicine.

Q: How should I store my Изокет medication?

A: Official information indicates that Изокет should be stored at a temperature not exceeding 25°C (77°F). It is important to keep the medicine in its original packaging to protect it from moisture and out of the reach of children. Checking the expiration date prior to use is a standard part of medication safety.

Q: Can Изокет be used for treating angina attacks?

A: Studies and official information indicate that Изокет is primarily used for the long-term management and prevention of angina (chest pain). It is generally not intended for the immediate, acute relief of a sudden angina attack, unlike some other related medications. Its primary role is the continuous prevention and reduction of the severity of future angina episodes.

Q: Does taking Изокет affect my driving ability?

A: According to the official product information, Изокет can impair the ability to drive or operate machinery, especially when first starting treatment or when the dosage is changed. This is due to potential side effects like headache, dizziness, or a drop in blood pressure. Official guidance emphasizes the need for caution, particularly at the beginning of treatment, as the effects on an individual's abilities may vary.

Official Storage and Disposal Guidelines

To ensure the stability and potency of Изокет (Isosorbide Dinitrate), official guidelines mandate strict adherence to storage and disposal rules.

Storage Conditions: Oral and sublingual forms must be kept at room temperature, typically specified as below 25°C, and kept from freezing. Store the medicine away from excess heat and moisture in its tightly closed, original container.

Special Handling: The concentrate for injection must be protected from light in its outer carton. For the infusion solution, PVC or PU administration sets must be avoided to prevent loss of the active ingredient.

Safety and Disposal: Always keep this medication out of the sight and reach of children, securing it with locked safety caps. For expired or unused medicine, consult a healthcare professional for specific disposal instructions. Do not dispose of the active substance in wastewater or household trash.